Goodrx Holdings Intrinsic Value Calculator – GOODRX HOLDINGS Reports Q2 FY2023 Financial Results on June 30, 2023
August 18, 2023
🌥️Earnings Overview
GOODRX HOLDINGS ($NASDAQ:GDRX) reported their financial results for the second quarter of FY2023, ending August 9 2023, on June 30 2023. Total revenue for the quarter was USD 189.7 million, representing a decrease of 1.1% compared to the same period of the prior year. The company’s reported net income was USD 58.8 million, a significant increase from the -1.4 million reported in the year prior.
Stock Price
On Wednesday, June 30, 2023, GOODRX HOLDINGS reported its financial results for the second quarter of the financial year 2023. The GOODRX HOLDINGS stock opened at $7.8 and closed at $7.9, a decrease of 9.2% from its prior closing price of 8.7. This decrease in stock value was largely attributed to the company’s poor performance in the second quarter, where it missed its revenue and earnings estimates. Despite this decline in performance, GOODRX HOLDINGS remains optimistic about its prospects for the remainder of the financial year.
This suggests that GOODRX HOLDINGS is confident that its performance will improve in the coming quarters. Overall, although GOODRX HOLDINGS missed its financial targets for the second quarter, it remains optimistic about its future prospects and is confident that it can achieve higher growth in the coming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Goodrx Holdings. More…
| Total Revenues | Net Income | Net Margin |
| 745.09 | 11.79 | 1.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Goodrx Holdings. More…
| Operations | Investing | Financing |
| 127.77 | -41.74 | -54.58 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Goodrx Holdings. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.69k | 796.73 | 2.26 |
Key Ratios Snapshot
Some of the financial key ratios for Goodrx Holdings are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 16.5% | -53.8% | 5.0% |
| FCF Margin | ROE | ROA |
| 9.3% | 2.7% | 1.4% |
Analysis – Goodrx Holdings Intrinsic Value Calculator
GoodWhale has conducted an in-depth analysis of GOODRX HOLDINGS‘ wellbeing. According to our calculations, the intrinsic value of GOODRX HOLDINGS share is around $26.0, calculated by our proprietary Valuation Line. This means that the current market price of $7.9 is substantially undervalued by 69.6%. We believe that this presents a good opportunity for investors to invest in the company at a discounted rate. We strongly advise our clients to take advantage of this unique opportunity and invest in GOODRX HOLDINGS. More…
Peers
The company’s competitors include Walgreens Boots Alliance Inc, Rite Aid Corp, and CVS Health Corp.
– Walgreens Boots Alliance Inc ($NASDAQ:WBA)
Walgreens Boots Alliance Inc is a global pharmacy-led, health and wellbeing enterprise. The company has a market cap of 29.66B as of 2022 and a ROE of 10.64%. Walgreens Boots Alliance is the largest retail pharmacy chain in the United States with over 8,000 stores in all 50 states. The company also has a strong international presence with over 4,000 stores in 25 countries.
– Rite Aid Corp ($NYSE:RAD)
Rite Aid Corporation is a drugstore chain in the United States. The company’s market cap is $237.45 million as of 2022. The company’s return on equity is 240.91%. Rite Aid Corporation operates drugstores in 31 states and the District of Columbia. The company offers a variety of products and services, including prescriptions, over-the-counter medications, health and beauty aids, personal care items, food and beverages, greeting cards, and convenience items.
– CVS Health Corp ($NYSE:CVS)
The company’s market cap is 121.73B as of 2022. The company’s ROE is 10.96%. CVS Health Corp is a company that provides healthcare services. The company operates through three segments: Pharmacy Services, Retail/LTC, and Corporate. The Pharmacy Services segment provides pharmacy benefit management services, mail order pharmacy services, and specialty pharmacy services. The Retail/LTC segment operates retail pharmacies, long-term care pharmacies, and retail clinics. The Corporate segment provides management and administrative services.
Summary
GoodRx Holdings recently reported their financial results for the second quarter of FY2023, ending August 9 2023. Total revenue decreased by 1.1% compared to the same period in the prior year. Net income increased significantly year-over-year, from a loss of -1.4 million to a gain of 58.8 million. Despite the improved financial performance, the stock price dropped on the same day of the report. Investors should consider the current market environment, along with GoodRx’s sustained revenue growth and positive net income trend, when making an investment decision.
Additionally, investors should assess the potential impact of future business initiatives and financial performance in order to make a well-informed decision.
